Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Teresa Helsten"'
Autor:
Rebecca A. Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B. Schwab, Emily I. Pittman, Minya Pu, Elizabeth Weihe, Emanuela M. Ghia, Laura Z. Rassenti, Alfredo Molinolo, Betty Cabrera, James B. Breitmeyer, George F. Widhopf, Karen Messer, Catriona Jamieson, Thomas J. Kipps, Barbara A. Parker
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024)
Abstract Background Zilovertamab is a humanized monoclonal antibody targeting ROR1, an onco-embryonic antigen expressed by malignant cells of a variety of solid tumors, including breast cancer. A prior phase 1 study showed that zilovertamab was well
Externí odkaz:
https://doaj.org/article/0486bdf60d074a82b6fba59959ed172b
Autor:
Denise M. Wolf, Jane Perlmutter, Judy C. Boughey, A. Jo Chien, Meredith Buxton, Gillian L. Hirst, Douglas Yee, Angela DeMichele, Andres Forero-Torres, Scott M. Berry, Erin D. Ellis, Anthony D. Elias, Julia Wulfkuhle, Michael Alvarado, Christina Yau, Stacy L. Moulder, Nola M. Hylton, Rita Nanda, Amy Wilson, Adam Asare, Debu Tripathy, Claudine Isaacs, Melissa Paoloni, Rosa I. Gallagher, Laura J. Esserman, Richard Schwab, W. Fraser Symmans, Cheryl Ewing, Laura J. van't Veer, Jeffrey B. Matthews, Teresa Helsten, Julia L. Clennell, Barbara Haley, Emanuel F. Petricoin, Katherine Steeg, Smita Asare, Ashish Sanil, Rachel L. Yung, Erin P. Crane, Erin Roesch, Hyo S. Han, Ruby Singhrao, Michelle E. Melisko, Hope S. Rugo, Kathy S. Albain, Donald A. Berry, Anne M. Wallace, Julie E. Lang, Amy S. Clark, Kathleen Kemmer, Lamorna Brown-Swigart
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature communications, vol 12, iss 1
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ad
Autor:
Hyo S. Han, Bridget Riley-Gillis, Teresa Helsten, Bella Kaufman, Yuan Yuan, Michael Friedlander, Meijing Wu, Cyril Ramathal, Véronique Diéras, Erin Murphy, Jean-Pierre M. Ayoub, Madan Gopal Kundu, Banu Arun, Christine K. Ratajczak, David Maag, Shannon Puhalla, Hans Wildiers, Vered Stearns
Publikováno v:
Clinical Cancer Research. 27:4983-4993
Purpose: Safety, efficacy, and exploratory biomarker analyses were evaluated in patients with advanced HER2-negative germline breast cancer susceptibility gene (gBRCA)-associated breast cancer enrolled in the BROCADE3 trial who received crossover vel
Autor:
Molinolo A. Alfred, Richard Schwab, Barbara A. Parker, Karen Messer, Ruifeng Chen, James B. Breitmeyer, Laura Z. Rassenti, Teresa Helsten, Rebecca Shatsky, Emily Pittman, Elizabeth Weihe, Emmanuela M. Ghia, Catriona Jamieson, Thomas J. Kipps, George F. Widhopf
Publikováno v:
Cancer Research. 80:P3-10
Background: Cirmtuzumab is a humanized monoclonal antibody that targets the receptor tyrosine kinase like orphan receptor 1 (ROR1), which is expressed on poor prognosis breast cancer, ovarian cancer, other solid tumors, CLL and mantle cell lymphoma.
Autor:
Paul Haluska, Melanie Catherine Majure, Denise M. Wolf, Rachel L. Yung, Paula R. Pohlmann, Hyo S. Han, Jeffrey B. Matthews, Michelle E. Melisko, A. Jo Chien, Andres Forero-Torres, Kristen K. Edmiston, Adam Asare, Hope S. Rugo, Laura J. van't Veer, Jane Perlmutter, Debu Tripathy, Gillian L. Hirst, Anne M. Wallace, Patricia A. Robinson, Rita A. Mukhtar, Julia L. Clennell, W. Fraser Symmans, Judy C. Boughey, Scott M. Berry, Douglas Yee, Rita Nanda, Claudine Isaacs, Anthony D. Elias, Christina Yau, Julia Wulfkuhle, Nola M. Hylton, Emanuel F. Petricoin, Karthik V. Giridhar, Ashish Sanil, Smita Asare, Barbara Haley, Lajos Pusztai, Heather Beckwith, Laura J. Esserman, Kathleen Kemmer, Erin D. Ellis, Lamorna Brown-Swigart, Meredith Buxton, Stacy L. Moulder, Melissa Paoloni, Teresa Helsten, Donald A. Berry, Carla I. Falkson, Kathy S. Albain, Amy S. Clark, Angela DeMichele, Erica Stringer-Reasor, Qamar J. Khan, Amy Wilson, Ruby Singhrao
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
NPJ breast cancer, vol 7, iss 1
NPJ Breast Cancer
NPJ breast cancer, vol 7, iss 1
NPJ Breast Cancer
I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a monoclonal an
Autor:
Laura J. van't Veer, Kathleen Kemmer, W. Fraser Symmans, Christina Yau, Barbara Haley, Janice Lu, S Asare, Erin D. Ellis, Nora Jaskowiak, Katherine Steeg, Erica Stringer-Reasor, Anthony D. Elias, Ashish Sanil, Donald W. Northfelt, Andres Forero-Torres, Constantine Godellas, Anne M. Wallace, Nola M. Hylton, Ruby Singhrao, Laura J. Esserman, Angela DeMichele, Donald A. Berry, Richard Schwab, Jane Perlmutter, Hope S. Rugo, Garry Peterson, Debasish Tripathy, Judy C. Boughey, Michelle E. Melisko, Meredith Buxton, Gillian L. Hirst, Teresa Helsten, Douglas Yee, Larissa A. Korde, Julia L. Clennell, Amy Wilson, Rebecca K. Viscusi, Rita Nanda, Claudine Isaacs, Henry G. Kaplan, Kathy S. Albain, Rashmi Murthy, Scott M. Berry, Melissa Paoloni, Julie E. Lang, Amy S. Clark, Jeffrey B. Matthews, Kirsten K. Edmiston, A. Jo Chien
Publikováno v:
J Clin Oncol
PURPOSEThe phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of survival and therapeutic resistance in breast cancer. We evaluated the pan-Akt inhibitor MK-2206 in combination with standard therapy in patients with high
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed9a9a2e1a4541afe98e7485020400cb
https://europepmc.org/articles/PMC7106976/
https://europepmc.org/articles/PMC7106976/